drugset / Trial / NCT03649061

COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA

NCT03649061

RandomizedParallel-groupOpen-labelTreatment

Summary

In the Care in Rheumatoid Arthritis (CareRA) trial (NCT01172639) about 70% of early RA patients are in remission at the 2 year evaluation point independent of the combination scheme used. Interesting to see is that the 30% of insufficient responders can be identified in an early stage of the treatment course. The purpose of the present study is to investigate if, for patients with an insufficient response to a COBRA-Slim regimen, accelerated access to a short course of anti-TNF therapy already early after treatment initiation (from w8 until w32) could improve outcomes compared to a more traditional treat to target sequence.

Timeline

Start
2018-06-08
Primary completion
2022-07-01
Completion
2022-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous
Comparator Leflunomide Small molecule 10 mg Oral

Indications